Abstract
Left heart disease (LHD) represents the most frequent cause of pulmonary hypertension (PH). In the past, rheumatic mitral valve disease was the most common cause of PH in left heart disease; however, today it is more likely to be associated with hypertensive and/or ischemic heart disease. However, there is currently no specific treatment for these patients. Some clinical trials have suggested the possibility in treatment of PH-LHD; some recent trials indicated that Rho-kinase inhibitor maybe a new hope. This review gives an overview of PH associated with left heart disease, and discusses the challenges associated with targeting drug treatment of PH-LHD. Key words: Pulmonary hypertension due to left heart disease; Pathophysiology; Target medication; Clinical Trial
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
